2-异丁氧基苯基硼酸 | 833486-92-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-异丁氧基苯基硼酸
• 中文别名: 2-异丁氧基苯硼酸
• 英文名称: (2-isobutoxyphenyl)boronic acid
• 英文别名: 2-Isobutoxyphenylboronic acid；[2-(2-methylpropoxy)phenyl]boronic acid
• CAS: 833486-92-3
• 化学式: C₁₀H₁₅BO₃
• 分子量: 194.038
• InChiKey: WROPRHAJDSQMRO-UHFFFAOYSA-N

物化性质

• 熔点：
  83-88 °C(lit.)
• 沸点：
  344.5±44.0 °C(Predicted)
• 密度：
  1.08±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2931900090
• 安全说明：
  S22,S24/25
• 危险性防范说明：
  P233,P260,P261,P264,P271,P280,P302+P352,P304,P304+P340,P305+P351+P338,P312,P321,P332+P313,P337+P313,P340,P362,P403,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-异丁氧基苯基硼酸 、 N-{[1-(5-bromopyridin-2-yl)piperidin-4-yl]methyl}-4-(5-cyano-7-isopropyl-1,3-benzoxazol-2-yl)benzamide 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 生成 4-(5-cyano-7-isopropylbenzo[d]oxazol-2-yl)-N-((1-(5-(2-isobutoxyphenyl)pyridin-2-yl)piperidin-4-yl)methyl)benzamide
  参考文献：
  名称：

  2-(4-Carbonylphenyl)benzoxazole inhibitors of CETP: Scaffold design and advancement in HDLc-raising efficacy

  摘要：

  The development of 2-phenylbenzoxazoles as inhibitors of cholesteryl ester transfer protein (CETP) is described. Initial efforts aimed at engineering replacements for the aniline substructures in the benchmark molecule. Reversing the connectivity of the central aniline lead to a new class of 2-(4-carbonylphenyl)benzoxazoles. Structure-activity studies at the C-7 and terminal pyridine ring allowed for the optimization of potency and HDLc-raising efficacy in this new class of inhibitors. These efforts lead to the discovery of benzoxazole 11v, which raised HDLc by 24 mg/dl in our transgenic mouse PD model. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.11.090

文献信息

• Furo[3,2‐<i>b</i>]pyridine: A Privileged Scaffold for Highly Selective Kinase Inhibitors and Effective Modulators of the Hedgehog Pathway
  作者：Václav Němec、Michaela Hylsová、Lukáš Maier、Jana Flegel、Sonja Sievers、Slava Ziegler、Martin Schröder、Benedict‐Tilman Berger、Apirat Chaikuad、Barbora Valčíková、Stjepan Uldrijan、Stanislav Drápela、Karel Souček、Herbert Waldmann、Stefan Knapp、Kamil Paruch

  DOI：10.1002/anie.201810312

  日期：2019.1.21

  of the furo[3,2‐b]pyridine core as a novel scaffold for potent and highly selective inhibitors of cdc‐like kinases (CLKs) and efficient modulators of the Hedgehog signaling pathway. Initially, a diverse target compound set was prepared by synthetic sequences based on chemoselective metal‐mediated couplings, including assembly of the furo[3,2‐b]pyridine scaffold by copper‐mediated oxidative cyclization

  据报道，呋喃[3,2-b]吡啶核是一种新型的支架，可作为有效且高度选择性的cdc-like激酶（CLKs）抑制剂和刺猬信号通路的有效调节剂。最初，基于化学选择性金属介导的偶联，通过合成序列制备了多样化的目标化合物，包括通过铜介导的氧化环化组装呋喃[3,2-b]吡啶骨架。含有3,5-二取代的呋喃[3,2-b]吡啶的亚系列的优化提供了有效的，细胞活性的和高度选择性的CLKs抑制剂。对3,5,7-三取代的呋喃并[3,2-b]吡啶的激酶无活性子集的分析揭示了Hedgehog途径的亚微摩尔调节剂。
• Hydrophobic substituents on isatin derivatives enhance their inhibition against bacterial peptidoglycan glycosyltransferase activity
  作者：Yong Wang、Wing-Lam Cheong、Zhiguang Liang、Lok-Yan So、Kin-Fai Chan、Pui-Kin So、Yu Wai Chen、Wing-Leung Wong、Kwok-Yin Wong

  DOI：10.1016/j.bioorg.2020.103710

  日期：2020.4

  small molecule inhibitor to the hydrophobic region of the membrane-bound bacterial cell wall synthesis enzyme and the plasma membrane. In the present study, a total of 20 new amphiphilic compounds were systematically designed and the relationship between molecular hydrophobicity and the antibacterial activity by targeting at PGT was demonstrated. The in vitro lipid II transglycosylation inhibitory effects

  Moenomycin A是著名的肽聚糖糖基转移酶（PGT）天然产物抑制剂，是一种两亲性大分子，分子量为1583 g / mol，作为药物的生物利用度相对较差。在寻找针对该酶的具有高抑制能力的小分子配体时，我们发现向细菌PGT的基于伊斯汀的抑制剂中添加疏水基团可显着改善其对酶的抑制作用以及其抗菌活性。酶促抑制作用的改善可归因于小分子抑制剂与膜结合细菌细胞壁合成酶和质膜的疏水区更好的结合。在目前的研究中，总共系统地设计了20种新的两亲化合物，并证明了针对PGT的分子疏水性与抗菌活性之间的关系。的研究了化合物II对脂质体E. coli PBP1b和MIC的体外脂质II转糖基化抑制作用（IC 50）。优化的结果包括对MSSA，MRSA 6微克/毫升的MIC值，枯草芽孢杆菌和12微克/ mL的大肠杆菌用靛红衍生物得到5米其具有335克/摩尔的分子量。
• [EN] MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR<br/>[FR] MODULATEURS DU RÉGULATEUR DE LA CONDUCTANCE TRANSMEMBRANAIRE DE LA MUCOVISCIDOSE
  申请人：VERTEX PHARMA

  公开号：WO2022076627A1

  公开（公告）日：2022-04-14

  This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure:, pharmaceutical compositions containing at least one such modulator, methods of treating CFTR mediated diseases, including cystic fibrosis using such modulators and pharmaceutical compositions, combination therapies and combination pharmaceuticals employing those modulators, and processes and intermediates for making such modulators.

  本公开提供囊性纤维化跨膜传导调节因子（CFTR）的调节剂，其具有以下核心结构：，包含至少一种这样的调节剂的药物组合物，使用这样的调节剂和药物组合物治疗CFTR介导的疾病，包括囊性纤维化的方法，使用这些调节剂的组合疗法和组合药物，以及制造这些调节剂的过程和中间体。
• Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives
  申请人：Cephalon, Inc.

  公开号：US20130296312A1

  公开（公告）日：2013-11-07

  This application relates, in part, to compounds of the general Formula I and/or salts thereof, wherein X, R 1A , R 1B , R 2 , R 3 , R 4 , and R 5 are as defined herein. The application also relates to compositions and methods of inhibiting at least JAK2 in subjects in recognized need thereof for the treatment of diseases or disorders for which inhibition of at least JAK2 is indicated.

  该应用程序部分涉及一般式I化合物和/或其盐，其中X、R1A、R1B、R2、R3、R4和R5的定义如本文所述。该应用程序还涉及组合物和方法，用于抑制至少在有需要的患者中的JAK2，以治疗需要抑制至少JAK2的疾病或疾病。
• Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
  申请人：Cephalon, Inc.

  公开号：US08633173B2

  公开（公告）日：2014-01-21

  This application relates, in part, to compounds of the general Formula I and/or salts thereof, wherein X, R1A, R1B, R2, R3, R4, and R5 are as defined herein. The application also relates to compositions and methods of inhibiting at least JAK2 in subjects in recognized need thereof for the treatment of diseases or disorders for which inhibition of at least JAK2 is indicated.

  本申请部分涉及一般式I的化合物和/或其盐，其中X，R1A，R1B，R2，R3，R4和R5如本文所定义。该申请还涉及组合物和方法，用于抑制受识别需要的受试者中至少JAK2的治疗疾病或障碍的治疗，对于这些疾病或障碍，抑制至少JAK2是有指示的。